Abstract
Iminodipropionitrile (IDPN) is a synthetic nitrile that produces permanent behavioral syndrome characterized by repetitive head movements, circling and back walking in rodents. Other synthetic nitriles of industrial importance such as crotonitrile and allylnitrile are also able to produce similar motor deficits in experimental animals. Among these nitriles, IDPN has been recognized as a prototype nitrile to be used as a positive control for behavioral testing battery. Due to the well-defined behavioral deficits and their easy quantification, IDPN-induced behavioral syndrome is a preferential animal model to test the interaction of various agents with synthetic nitriles. The mechanism of IDPN-induced dyskinesia is multifactorial. This short review focuses on the roles of neurotransmitters, oxidative stress and inflammation in the pathogenesis of IDPN-induced neurotoxicity and behavioral deficits.
Similar content being viewed by others
REFERENCES
Chou, S.M. and Hartmann, H.A., Acta Neuropathol., 1964, vol. 3, pp. 428–450.
Clark, A.W., Griffin, J.W., and Price, D.L., J. Neuropathol. Exp. Neurol., 1980, vol. 39, pp. 42–55.
Llorens, J., Demêmes, D., and Sans, A., Toxicol. Appl. Pharmacol., 1993, vol. 123, pp. 199–210.
Khan, H.A., Al Deeb, S., Al Moutaery, K., and Tariq, M., Exp. Toxicol. Pathol., 2003, vol. 55, pp. 181–186.
Khan, H.A., Exp. Toxicol. Pathol., 2012, vol. 64, pp. 791–796.
Tariq, M., Khan, H.A., Al Deeb, S., and Al Moutaery, K., Neurosci. Lett., 1999, vol. 276, pp. 49–52.
Khan, H.A. and Ibrahim, K.E., Arch. Med. Sci., 2015, vol. 11, pp. 1137-1144.
Ibrahim, K.E., Khan, H.A., and Omer, F.A., Exp. Toxicol. Pathol., 2014, vol. 66, pp. 89–96.
Wakata, N., Araki, Y., Sugimoto, H., Iguchi, H., and Kinoshita, M., Neurochem. Res., 2000, vol. 25, pp. 401–404.
Tariq, M., Khan, H.A., Al Moutaery, K., and Al Deeb, S., Exp. Neurol., 1999, vol. 158, pp. 229–233.
Cadet, J.L., Jackson-Lewis, V., and Fahn, S., Brain Res., 1988, vol. 456, pp. 371–374.
Cadet, J.L., and Karoum, F., Synapse., 1988, vol. 2, pp. 23–27.
Ogawa, N., Mizukawa, K., Haba, K., and Sato, H., Eur. Neurol., 1990, vol. 30, pp. 31–40.
Hirata, H., Ogawa, N., Asanuma, M., Ota, Z., and Mori, A., Brain Res., 1993, vol. 604, pp. 197–204.
Ogawa, N., Haba, K., Asanuma, M., and Mori, A., Brain Res., 1991, vol. 556, pp. 271–279.
Khan, H.A., Alhomida, A.S., and Arif, I.A., Toxicol. Sci., 2009, vol. 109, pp. 124–131.
Fornai, F., Alessandri, M.G., Saginario, A., Vaglini, F., and Corsini, G.U., Brain Res., 1993, vol. 605, pp. 93–100.
Tariq, M., Khan, H.A., Moutaery, K.A., and Deeb, S.A., J. Appl. Toxicol., 1999, vol. 19, pp. 93–99.
Perumal, A.S., Gopal, V.B., Tordzro, W.K., and Cadet, J.L., Brain Res. Bull., 1991, vol. 26, pp. 653–655.
Nomoto, N., J. Neurol. Sci., 2004, vol. 219, pp. 41–44.
Tariq, M., Khan, H.A., Rehana, Z., Al Moutaery, K., and Al Deeb, S., Neurotoxicol. Teratol., 1998, vol. 20, pp. 571–579.
Al Deeb, S., Al Moutaery, K., Khan, H.A., and Tariq, M., Neurotoxicol. Teratol., 2000, vol. 22, pp. 213–220.
Tariq, M., Khan, H.A., Al Moutaery, K., and Al Deeb, S., Behav. Pharmacol., 2004, vol. 15, pp. 585–588.
Tariq, M., Al-Deeb, S., Al-Moutairy, K., and Ahmad Khan, H., Int. J. Neurosci., 1995, vol. 83, pp. 165–175.
Lohr, J.B., Cadet, J.L., Wyatt, R.J., and Freed, W.J., Neuropsychopharmacology., 1988, vol. 1, pp. 305–309.
Hsiao, H.Y., Chen, Y.C., Chen, H.M., Tu, P.H., and Chern, Y., Hum. Mol. Genet., 2013, vol. 22, pp. 1826–1842.
Herlofson, K., Heijnen, C.J., Lange, J., Alves, G., Tysnes, O.B., Friedman, J.H., and Fagundes, C.P., Acta. Neurol. Scand., 2018, vol. 138, pp. 394–399.
Paouri, E., and Georgopoulos, S., Curr. Alzheimer Res., 2019, vol. 16, pp. 559–574.
Del-Bel, E., Bortolanza, M., Dos-Santos-Pereira, M., Bariotto, K., and Raisman-Vozari, R., Synapse., 2016, vol. 70, pp. 479–500.
de Groot, N.S., and Burgas, M.T., Cell. Mol. Life Sci., 2015, vol. 72, pp. 4795–4805.
Colpo, G.D., Rocha, N.P., Stimming, E.F., and Teixeira, A.L., CNS Neurol. Disord. Drug Targets., 2017, vol. 16, pp. 936–944.
Leonoudakis, D., Rane, A., Angeli, S., Lithgow, G.J., Andersen, J.K., and Chinta, S.J., Mediat. Inflamm., 2017, vol. 2017, 8302636.
Cayero-Otero, M.D., Espinosa-Oliva, A.M., Herrera, A.J., Garcia-Dominguez, I., Fernandez-Arevalo, M., Martin-Banderas, L., and de Pablos, R.M., Curr. Pharm. Des., 2018, vol. 24, pp. 1589–1616.
Tariq, M., Khan, H.A., Siddiquei, M.M., Al Moutaery, K., and Al Deeb, S., Basic Clin. Pharmacol. Toxicol., 2007, vol. 100, pp. 176–181.
Al Kadasah, S., Al Mutairy, A., Siddiquei, M., Khan, H.A., Abdulwahid Arif, I., Al Moutaery, K., and Tariq, M., Behav. Pharmacol., 2009, vol. 20, pp. 356–360.
Tariq, M., Khan, H.A., Al Moutaery, K., and Al Deeb, S., Pharmacol. Biochem. Behav., 2002, vol. 73, pp. 647–654.
Funding
No external funding was received.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest. The authors declare that they have no conflict of interest.
Ethical approval. This is a review article and therefore does not require ethical approval.
Rights and permissions
About this article
Cite this article
Sara T. Alrashood, Elrobh, M.S., Alamery, S. et al. A Short Review of Biochemical Mechanisms in Iminodipropionitrile-Induced Movement Disorder. Neurochem. J. 14, 9–12 (2020). https://doi.org/10.1134/S1819712420010031
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1134/S1819712420010031